Valeant Pharmaceuticals Intl Inc (VRX) Given Consensus Rating of “Hold” by Brokerages

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) has received a consensus recommendation of “Hold” from the twenty-four brokerages that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $18.26.

A number of equities analysts recently commented on VRX shares. Vetr downgraded shares of Valeant Pharmaceuticals Intl from a “strong-buy” rating to a “sell” rating and set a $13.30 target price for the company. in a research note on Thursday, August 24th. Mizuho reiterated a “sell” rating and set a $7.00 target price (down previously from $8.00) on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, August 29th. Cantor Fitzgerald reiterated a “buy” rating and set a $23.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, August 29th. ValuEngine downgraded shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Piper Jaffray Companies reiterated a “sell” rating and set a $14.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Sunday, September 17th.

In other Valeant Pharmaceuticals Intl news, Director John Paulson bought 344,216 shares of Valeant Pharmaceuticals Intl stock in a transaction dated Thursday, November 16th. The stock was acquired at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the acquisition, the director now owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.87% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in VRX. Riggs Asset Managment Co. Inc. raised its holdings in shares of Valeant Pharmaceuticals Intl by 118.2% in the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 4,512 shares during the last quarter. Cetera Investment Advisers purchased a new stake in shares of Valeant Pharmaceuticals Intl in the second quarter valued at about $192,000. Harbour Capital Advisors LLC purchased a new stake in shares of Valeant Pharmaceuticals Intl in the third quarter valued at about $224,000. American Century Companies Inc. purchased a new stake in shares of Valeant Pharmaceuticals Intl in the third quarter valued at about $238,000. Finally, Moors & Cabot Inc. raised its holdings in shares of Valeant Pharmaceuticals Intl by 32.3% in the second quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock valued at $267,000 after buying an additional 3,725 shares during the last quarter. 49.45% of the stock is owned by institutional investors and hedge funds.

Valeant Pharmaceuticals Intl (VRX) opened at $20.89 on Thursday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. The company has a market cap of $7,270.00, a price-to-earnings ratio of 3.45, a P/E/G ratio of 0.58 and a beta of -0.22. Valeant Pharmaceuticals Intl has a 12 month low of $8.31 and a 12 month high of $22.81.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2018/01/13/valeant-pharmaceuticals-intl-inc-vrx-given-consensus-rating-of-hold-by-brokerages.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply